Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Aged
Disease Progression
Female
Humans
Indoles
/ adverse effects
Lung
/ diagnostic imaging
Lung Diseases, Interstitial
/ diagnostic imaging
Male
Middle Aged
Phenotype
Pulmonary Fibrosis
/ diagnostic imaging
Pyridones
/ adverse effects
Retrospective Studies
Risk Factors
Tertiary Care Centers
Tomography, X-Ray Computed
IPAF
Interstitial lung disease
Nintedanib
Pirfenidone
Progressive fibrosing interstitial lung diseases
Real-world experience
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
26
07
2019
accepted:
11
09
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
30
4
2020
Statut:
epublish
Résumé
Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators. However, response to these therapies is highly variable, sometimes without meaningful improvement, especially in more fibrosing forms. Pirfenidone and nintedanib have recently demonstrated to reduce functional decline in patients with IPF. However, their antifibrotic mechanism makes these two drugs an interesting approach for treatment of fibrosing ILDs other than IPF. We here report our experience with antifibrotic drugs in fibrosing non-IPF ILDs patients having a progressive phenotype during immunosuppressive therapy. Patients with a multidisciplinary team diagnosis of fibrosing non-IPF ILDs experiencing a progressive phenotype during treatment with corticosteroids and/or immunomodulators between October-2014 and January-2018 at our tertiary referral Center for ILDs were retrospectively analyzed. Antifibrotic therapy was administered after application with the respective health insurance company and after consent by the patient. Pulmonary-function-tests and follow-up visits were performed every 6 ± 1 months. Eleven patients were treated with antifibrotic drugs (8 males, mean age 62 ± 12.8 years, mean FVC% 62.8 ± 22.3, mean DLCO% 35.5 ± 10.7, median follow-up under antifibrotic treatment 11.1 months). Patients had a diagnosis of unclassifiable ILD in 6 cases, pleuroparenchymal fibroelastosis in 2 cases, idiopathic-NSIP in 1 case, asbestos-related ILD in 1 case and Hermansky-Pudlak syndrome in 1 case. Treatment before antifibrotics consisted of corticosteroids in all patients: 5 combined with Azathioprin, 1 with either methotrexate or cyclophosphamide (i.v.). Ten patients were treated with pirfenidone (2403 mg/die) and 1 with nintedanib (300 mg/die). Median FVC was 56, 56, 50%, at time points - 24, - 12, - 6 before initiation, 44% at time of initiation and 46.5% at 6 months after initiation of antifibrotic treatment. Antifibrotic treatment was generally well tolerated with a need of dose reduction in 2 cases (rash and nausea) and early termination in 3 cases. Antifibrotic treatment may be a valuable treatment option in patients with progressive fibrosing non-IPF ILD if currently no other treatment options exist. However, prospective, randomized clinical trials are urgently needed to assess the real impact of antifibrotic therapy in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators. However, response to these therapies is highly variable, sometimes without meaningful improvement, especially in more fibrosing forms. Pirfenidone and nintedanib have recently demonstrated to reduce functional decline in patients with IPF. However, their antifibrotic mechanism makes these two drugs an interesting approach for treatment of fibrosing ILDs other than IPF.
OBJECTIVES
OBJECTIVE
We here report our experience with antifibrotic drugs in fibrosing non-IPF ILDs patients having a progressive phenotype during immunosuppressive therapy.
METHODS
METHODS
Patients with a multidisciplinary team diagnosis of fibrosing non-IPF ILDs experiencing a progressive phenotype during treatment with corticosteroids and/or immunomodulators between October-2014 and January-2018 at our tertiary referral Center for ILDs were retrospectively analyzed. Antifibrotic therapy was administered after application with the respective health insurance company and after consent by the patient. Pulmonary-function-tests and follow-up visits were performed every 6 ± 1 months.
RESULTS
RESULTS
Eleven patients were treated with antifibrotic drugs (8 males, mean age 62 ± 12.8 years, mean FVC% 62.8 ± 22.3, mean DLCO% 35.5 ± 10.7, median follow-up under antifibrotic treatment 11.1 months). Patients had a diagnosis of unclassifiable ILD in 6 cases, pleuroparenchymal fibroelastosis in 2 cases, idiopathic-NSIP in 1 case, asbestos-related ILD in 1 case and Hermansky-Pudlak syndrome in 1 case. Treatment before antifibrotics consisted of corticosteroids in all patients: 5 combined with Azathioprin, 1 with either methotrexate or cyclophosphamide (i.v.). Ten patients were treated with pirfenidone (2403 mg/die) and 1 with nintedanib (300 mg/die). Median FVC was 56, 56, 50%, at time points - 24, - 12, - 6 before initiation, 44% at time of initiation and 46.5% at 6 months after initiation of antifibrotic treatment. Antifibrotic treatment was generally well tolerated with a need of dose reduction in 2 cases (rash and nausea) and early termination in 3 cases.
CONCLUSIONS
CONCLUSIONS
Antifibrotic treatment may be a valuable treatment option in patients with progressive fibrosing non-IPF ILD if currently no other treatment options exist. However, prospective, randomized clinical trials are urgently needed to assess the real impact of antifibrotic therapy in these patients.
Identifiants
pubmed: 31718637
doi: 10.1186/s12890-019-0937-0
pii: 10.1186/s12890-019-0937-0
pmc: PMC6852748
doi:
Substances chimiques
Indoles
0
Pyridones
0
pirfenidone
D7NLD2JX7U
nintedanib
G6HRD2P839
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213Références
Eur Respir Rev. 2017 Oct 3;26(145):null
pubmed: 28974541
Lung. 2019 Apr;197(2):147-153
pubmed: 30758708
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Eur Respir J. 2016 Jan;47(1):243-53
pubmed: 26647432
Eur Respir Rev. 2013 Mar 1;22(127):6-19
pubmed: 23457159
Semin Respir Crit Care Med. 2016 Jun;37(3):358-67
pubmed: 27231860
Eur Respir Rev. 2018 Dec 21;27(150):null
pubmed: 30578335
Eur Respir J. 2019 Mar 7;53(3):null
pubmed: 30578385
Arthritis Rheumatol. 2014 Aug;66(8):1967-78
pubmed: 24838199
PLoS One. 2015 Jun 25;10(6):e0130653
pubmed: 26110421
Eur Respir Rev. 2018 Dec 21;27(150):null
pubmed: 30578333
Mol Genet Metab. 2018 Sep;125(1-2):168-173
pubmed: 30055995
N Engl J Med. 2011 Sep 22;365(12):1079-87
pubmed: 21992121
BMJ Open Respir Res. 2017 Sep 17;4(1):e000212
pubmed: 29018526
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
BMJ Open Respir Res. 2018 Sep 4;5(1):e000289
pubmed: 30233802
Eur Respir Rev. 2018 May 2;27(148):null
pubmed: 29720509
Respir Med. 2019 Apr;150:154-160
pubmed: 30961944
J Rheumatol. 2016 Sep;43(9):1672-9
pubmed: 27370878
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Eur Respir J. 2015 Oct;46(4):976-87
pubmed: 26160873
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Curr Opin Pulm Med. 2017 Sep;23(5):418-425
pubmed: 28622199
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Acta Reumatol Port. 2019 May 18;44(2):161-162
pubmed: 31280278
BMC Pulm Med. 2017 Sep 6;17(1):122
pubmed: 28877715
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81
pubmed: 28664834